The Personal Care Products Safety Act introduced in the Senate May 11, and the Cosmetic Modernization Amendments Act that launched in the House earlier this year, closely mirror versions that divided big and small business in the last Congress. So while the US political environment may be dramatically changed, the legislative situation for stakeholders seeking updated cosmetics regulations, at the moment, is not.
Cosmetics trade groups seem intent on reaching consensus in their legislative efforts to update US regulations, but the two proposals thus far in the 115th Congress are identical in most respects to those in the previous session that divided industry along big and small business lines.
The Cosmetic Modernization Amendments of 2017, introduced in the House in January by Rep. Pete Sessions, R-Texas, closely mirrors the...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
